Related Experiment Videos

Optimal timing of pediatric heart transplantation

L J Addonizio1, D T Hsu, L Fuzesi

  • 1Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, New York.

Circulation
|November 1, 1989
PubMed

Insights

Pediatric heart transplantation outcomes improve when patients avoid pulmonary hypertension and hemodynamic decompensation. Combined preoperative pulmonary hypertension and hemodynamic decompensation significantly predict mortality in pediatric heart transplant recipients.

Area of Science:

  • Pediatric Cardiology
  • Transplantation Medicine
  • Critical Care Medicine

Background:

  • Heart transplantation (HT) in children is often viewed as a last resort.
  • Many pediatric HT candidates present with significant comorbidities.
  • Pulmonary hypertension (PH) and hemodynamic decompensation (HD) are common in pediatric HT recipients.

Purpose of the Study:

  • To retrospectively analyze the impact of preoperative PH and HD on pediatric heart transplant survival.
  • To identify preoperative risk factors affecting survival in pediatric heart transplant recipients.
  • To evaluate the combined effect of PH and HD on post-transplant outcomes.

Main Methods:

  • Retrospective review of 30 pediatric patients undergoing HT (age 5 days to 18 years).
  • Cox proportional-hazards analysis of nine potential risk factors, including PH and HD.
  • Assessment of one-year actuarial survival rates based on preoperative conditions.

Main Results:

  • Overall one-year survival was 66%.
  • Patients without PH or HD had 100% one-year survival.
  • The combined presence of PH and HD was a highly significant predictor of mortality (RR 4.08, p<0.002), with 30% survival compared to 84% in those without.

Conclusions:

  • Preoperative PH and HD are critical factors influencing pediatric heart transplant outcomes.
  • Avoiding PH and HD pre-transplant is associated with significantly improved survival.
  • These findings highlight the importance of managing PH and HD in pediatric end-stage heart disease to optimize HT candidacy and outcomes.

Related Concept Videos